Archives202520242023202220212020201920182017201620152014201320122011 April 29, 2021FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2020 Read More February 09, 2021Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 Read More January 18, 2021Appointment of Company Secretary Read More January 04, 2021Lanstead Capital TR1 Read More December 03, 2020ImmuPharma to present at Biotech Showcase™ Digital 2021 Read More November 30, 2020Total Share Capital Notification Read More November 26, 2020Grant of Share Options & PDMR dealing Read More November 24, 2020Conversion of Convertible Security Read More November 23, 2020Conversion of Convertible Security Read More November 20, 2020FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients Read More November 19, 2020Total Share Capital Notification Read More November 10, 2020Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients Read More 1…89101112…24
February 09, 2021Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 Read More
November 20, 2020FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients Read More
November 10, 2020Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients Read More
